Just about to give our first liso-cel doses so this is good to see!
08.07.2025 14:16
👍 1
🔁 0
💬 0
📌 0
Just about to give our first liso-cel doses so this is good to see!
Fujimoto et al - Allo / auto in ENKT? Japanese data.
• if in CR, ASCT appear superior to allo
• if in PR, allo appears preferable
• no impact on source of allo cells
I normally allo these pts in CR1 so potentially practise changing.
#18ICML #ICML25 #lymsm
Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL
• 76 pts part of bigger trial
• PFS no diff but was ⬆️ when MVA performed
• responses ⬆️
• BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths.
Doubt there will be further development.
#18ICML #ICML25 #lymsm
Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim
• global Ph 1B
• med age 72y
• at RP2D, ORR 100%, CRR 80%
• no G3+ CRS, 8% ICANs
Very impressive results
#18ICML #ICML25 #lymsm
Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm
Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm
Davison et al - PRO substudy of S1826 substudy. Interesting outputs:
• NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold.
• BV-AVD showed excess neuropathy which had a clinically meaningful impact.
#ICML25 #lymsm
Evans et al: E-HIPI prognostic score early cHL
• Holistic consortium
• 1 binary factor: female sex better prog
• 3 continuous: max tumour diam, Hb and albumin. Great work from
Online calculator now available!
#18ICML #ICML25 #lyms
Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome.
Take home message: if safe to use dox then do use it!
#18ICML #ICML25 #lymsm
Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL
• flow cytometry based
• MRD- most rapid with BR
• with RCHOP, even MRD- pts do poorly
• with IR, no assocn with MRD & outcome
#18ICML #ICML25 #lymsm
Flerlage et al
• GLOW data nod LPHL
• completely resected 1A, RT assoc with ⬆️ PFS compared with observation
• unresected - ABVD-RT & RT do v well
• no infield relapses if RT given
Great work which significantly informs practice. #18ICML #ICML25
#lymsm
Rossi et al - baseline MTV, Dmax & esp combo, assoc with PFS.
Independent effect of IPSS.
Both factors improve prognostic impact of iPET.
Based on AHL2011 study so all have 2x eacBEACOPDac as 1st 2 cycle.
#18ICML #ICML25
Herrera et al - ctDNA in S1826
• 97% ctDNA + baseline
• clearance at C3D1 assoc with PFS
• within pos pts, those with minor ⬇️ assoc with esp poor outcomes
• EOT ctDNA detection also assoc with poor outcomes
CtDNA ripe for response adapted trials.
#18ICML #ICML25 #lymsm
Ahmed et al - EBV & cHL subtype in S1826 study
• EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked)
• non-NS histology also benefited more from NAVD.
Biology is important!
#lymsm #18ICML #ICML25
Things are hotting up for the first of 2 #Hodgkin lymphoma sessions today.
#18ICML #ICML25 #lymsm
Ah shame - but perhaps not surprising.
A no. of trials in RR DLBCL with RGemOx as comparator all show:
• PFS med 2-3 mo
• OS med 12-13 mo
Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc.
Beaten by exptl arms in StarGlo, Polargo, Sunmo
Take home: no more RGemOx pls - it’s defeated!
#18ICML #lymsm
Feldman et al - acimtamig (CD16/CD30 engager) with alloNK in RR #Hodgkin
• 24 pts, heavily preRx
• ORR 88%, CRR 58%
• 25% CRS with 1 G3, no ICANs or GvH
Looks very active. Interested to see how it will developed further.
#18ICML
Shah et al - Zamto-cel 3L+ DLBCL
• tandem CD19 / CD20 41BB construct
• non cryopreserved, short vein-vein
• 69 pts
• ORR 73%, CRR 51%
• no G3+ CRS, 4% G3+ ICANS
Clearly active but is it better than current agents?
#18ICML
Sancho et al - POLARGO.
• RGemOx vs Pola-RGemOx R/R DLBCL
• 2L+ DLBCL (no ASCT eligible if 2L)
• OS primary EP: signif adv 12.5mo vs 19.5mo
• PFS & CMR rate better
• tox modest - ⬆️ infn & PN
• no effect of cell of origin
Interesting but ? value if 1L PolaRCHP
#18ICML
Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18
@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with
• exhausted T-cells
• super-activated macrophages.
#ICML18
The EBV results are striking. Do have any biological hypotheses as to why we see the difference Paul?
Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access!
#lymsm
ascopubs.org/doi/10.1200/...
Lovely article Paul - congratulations
Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua
onlinelibrary.wiley.com/doi/10.1111/...
It’s the unboxing of the eighth edition of Hoffbrands Postgraduate Haematology. A real honour to be an editor alongside Adam Mead, Deborah Hay, Mike Lanffan and of course Victor Hoffbrand. Do get your copy!
Delighted to be sharing the stage with the great @broeckelmann.bsky.social at the 10th International Congress on Leukemia, Lymphoma and Myeloma. An erudite overview of the 1L setting - I’ve been given relapsed disease. #lymsm
Great to see this is in print!